IDH1 and astrocytoma (excluding glioblastoma): Poor prognostic indicators. IDH-mutant astrocytoma, with a CNS WHO grade of 4, is strongly associated with malignant transformation and poor outcomes. GBM patients with unmethylated MGMT promoters also have a poorer prognosis.